Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET
Company Participants
Donald Notman – CFO
Antony Mattessich – President, CEO & Director
Rabia Ozden – Chief Medical Officer
Conference Call Participants
Jonathan Wolleben – JMP Securities
Stacy Ku – Cowen and Company
Yi Chen – H.C. Wainwright & Co.
Joseph Catanzaro – Piper Sandler & Co.
Operator
Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Ocular Therapeutix Second Quarter 2022 Earnings Conference Call. [Operator Instructions]. It is now my pleasure to turn the call over to Donald Notman, Chief Financial Officer of Ocular Therapeutix. Please go ahead, sir.
Donald Notman
Thank you, operator. Good afternoon, everyone, and thank you for joining us on our second quarter 2022 financial results and business update conference call. This afternoon, after the close, we issued a press release providing an update on the company’s product development programs and details of the company’s financial results for the quarter ended June 30, 2022. The press release can be accessed on the Investors portion of our website at investors.ocutx.com.
Leading the call today will be Antony Mattessich, our President and Chief Executive Officer. We will provide an update on the commercial progress of DEXTENZA and a summary of our corporate developments. Also speaking on the line today will be Dr. Rabia Ozden, our Chief Medical Officer, who will give an update on our clinical developments and pipeline. Following Rabia’s remarks, I will provide an overview of the financial highlights for the quarter before turning the call back over to Anthony for a summary and questions.
For Q&A, we will be joined by Chris White, our Chief Business Officer; and Scott Corning, our Senior Vice President, Commercial. As a reminder, on today’s call, certain statements we will be making may be considered forward-looking for the purposes of the Private Securities Litigation Reform Act of 1995. In particular, any statements regarding our regulatory and product development plans as well as our research activities and our financial projections are forward-looking statements. These statements are subject to a variety of risks and uncertainties that may cause actual results to differ from those forecasted, including those risks described in our most recent quarterly report filed this afternoon with the SEC and our annual report on Form 10-K filed on February 28 with the SEC.
I will now turn the call over to Antony.
Antony Mattessich
Thanks, Tom. The second quarter of 2022 was another quarter of great progress in Ocular Therapeutix, most notably in the development of our pipeline. For those of you following the Ocular story, you’ll know that by far the most anticipated development for the company and for the hope of a more durable treatment for patients with wet AMD is our U.S.-based Phase I clinical trial for OTX-TKI, our existent containing hydrogel implant for treatment of wet AMD and other retinal diseases.
We are developing OTX-TKI to reset the standard of care for durability of a single injection in the treatment of wet AMD from 2 to 3 months to 6 months and beyond. To assess this, we have embarked upon a very important study in the U.S., comparing a single injection of OTX-TKI against Aflibercept dosed every 8 weeks. I’m delighted to announce that all 21 patients in the study have now been on study for 24 weeks or more, and we plan to perform an analysis after 28 weeks. The trial plan dovetails nicely with the American Academy of Ophthalmology meeting in Chicago where we have already been granted a late breaker slot on Friday, September 30.
While OTX-TKI is our lead program in retinal disease, we also have R&D efforts seeking to develop more durable treatments for geographic atrophy and gene therapy delivery platforms that minimize inflammatory risk and maximize transaction potential. To help pool all of our retina assets together, we are delighted to announce the addition of Dr. Peter Kaiser to the Ocular team as our Chief Medical Adviser, Retina, with Peter added to the considerable retinal expertise already at Ocular. We believe we are in a position to plan an optimal path forward for OTX-TKI as well as other in-house programs or any potential collaborations in the retina space.
On the glaucoma front, OTX-TIC our travel pros containing intracanal implants being developed for the treatment of open-angle glaucoma or ocular hypertension to improve patient compliance continues to enroll its first Phase II trial. We have designed this trial to assess the safety, tolerability and efficacy of OTX-TIC.
In our completed Phase I clinical trial, we observed that OTX-TIC did not harm endothelial cells. So we are developing OTX-TIC for chronic or repeat dosing. While this program seldom gets the attention of a sibling OTX-TKI, we are equally enthusiastic by its prospects.
In the treatment of dry eye disease, we have 2 programs, OTX-CSI, our cyclosporin contain intramolecular insert for the chronic treatment of dry eye disease and OTX-DED, our dexamethasone containing intracanalicular insert for the short-term treatment of the signs and symptoms of dry eye disease. While we’d like to advance both programs, we are acutely aware of the need to preserve cash in the current challenging financial environment and a need to find ways to improve our chances for success in the very difficult regulatory environment of dry eye disease. As a way to continue momentum on these programs while satisfying both objectives, we plan to embark upon a small trial with OTX-DED that will pioneer a trial design to test OTX-DED against a more appropriate placebo comparator.
Simultaneously, we are developing new formulations for OTX-CSI designed to be retained longer than the counter length of dose. Finally, helping to favor the development of our exciting pipeline is our commercial business with DEXTENZA, for the second quarter, DEXTENZA recorded net product revenue of $12.1 million, a 9% improvement over the same quarter of prior year and down slightly compared to the prior quarter. We were seeing both in the market and also with our own field force is that staffing levels continue to be a drag on potential growth. Despite the sluggishness of the current market, we are optimistic about the final quarters of the year and continue our guidance of between $55 million and $60 million of net product revenue for the full year.
Beyond this, we are also very happy that the recent outpatient prospective payment system or OPPS, proposed rule stated that DEXTENZA should remain separately payable in the ASC through 2023. As a result, we are optimistic that we can continue to grow our surgical business as we add to the future potential of the office environment. In summary, we’re making great progress at Ocular and are gearing up for a significant moment in our history with presentation of the results of our U.S.-based OTX-TKI Phase I trial in late September. To go into more detail on the pipeline, I’ll hand over to our newly promoted Chief Medical Officer, Dr. Rabia Ozden, our very own, Dr. Ozden.
Rabia Ozden
Thanks, Antony. Let me begin with an update on our back-of-the-eye program, OTX-TKI. In February, we presented an update from the ongoing Australia-based Phase I trial of OTX-TKI for the treatment of wet AMD and at the Angiogenesis exudation and Generation 2022 meeting. As background, this study was designed to assess the safety and tolerability of OTX-TKI and preliminary biological activity. Our goal for the study was to answer the question, can a tyrosine kinase inhibitor administered intravitreally as the monotherapy show biological activity in wet AMD?
We believe the best way to show this is to start with patients with active top retinal and/or intraretinal fluid and follow them to see if OTX-TKI can eliminate that fluid. This is the patient population that was enrolled in this Australian study. The data we shared at androgenesis was very encouraging and we found a clinically meaningful decrease in intraretinal and/or separate suit in many subjects and in some subjects, fluid was eliminated entirely.
In addition, extended duration of activity of 6 months or more was observed in over 60% of subjects across all cohorts and over 80% of subjects in cohort 3A 600 micrograms, which we believe could represent a compelling draft product profile. We are also currently running a U.S.-based Phase I clinical trial that is now fully enrolled. This is a multicenter prospective randomized controlled trial that is evaluating a 600-microgram OTX-TKI dose in a single implant containing axitinib compared to Aflibercept, administered every 8 weeks in subjects previously treated with anti-VEGF therapy and without in an intraretinal or subretinal fluid. In other words, with already dry retina.
This clinical trial is being conducted under an exploratory IND application. It’s 6 sites targeting a total of 20 randomized subjects with 3:1 randomization weighted towards OTX-TKI treated subjects. The trial is designed to assess the safety, durability and tolerability of OTX-TKI and to assess preliminary biological activity in subjects by measuring anatomical and functional changes on the retina. Our bond in this trial is to answer the question of how long a single 600-microgram OTX-TKI implant containing axitinib, keep subjects dry without the need for retreatment. We look forward to reporting to any — a big data at the upcoming AAO meeting at the end of September.
We believe achieving a similar response rate and durability to that seen in the Australia-based study would represent a compelling drug product profile. Moving to our glaucoma program, OTX-TIC. We recently presented data from the completed U.S.-based Phase I clinical trial evaluating the safety, biological activity, durability and tolerability of OTX-TIC in subjects with primary open angle glaucoma or ocular hypertension at the Glaucoma 360 meeting held on February 11.
We believe the Phase I data showed that OTX-TIC caused a clinically meaningful decrease in intraocular pressure, or IOP, comparable to trooperost as early as 2 days following administration. And for as long as 6 or more months with a single implant, while preserving corneal half, representing its potential for a novel and differentiated drug product profile. With this data in hand, we have initiated and are actively dosing subjects in a U.S.-based Phase II clinical trial.
This trial is a prospective multicenter randomized controlled trial evaluating the safety, tolerability and efficacy of OTX-TIC for the treatment of patients with primary open-angle glaucoma or ocular hypertension. The trial will enroll approximately 105 subjects in 3 different arms, about 35 subjects per arm randomized 1:1:1, in which the subjects will receive a single OTX-TIC implant containing a 5-microgram or 26-microgram dose of trooperost compared with an implant of [indiscernible].
The 5-microgram arm is utilizing a fast degrading implant, while the 26-microgram arm is utilizing a standard degrading implant. The trial will observe the changes in tonal IOP from baseline at 8 a.m., 10 a.m., 4:00 p.m., at 2, 6 and 12 weeks and follow duration of IOP response over time.
Regarding our ocular surface disease programs, we remain committed to the development of our 2 dry eye program, OTX-DED and low-dose intracanalicular insert containing dexamethasone for the short-term treatment of the signs and symptoms of dry eye disease and OTX-CSI, a cyclosporin intracanalicular insert for the chronic treatment of patients with the dry eye disease. With regard to OTX-DED, we intend to conduct a small trial to evaluate the performance of OTX-DED versus short duration biodegradable collagen implants.
Specifically, the intent for the trial to explain the magnitude of the placebo effect seen in both the OTX-DED and the OTX-CSI Phase II trial in which the vehicle hydrogen placebo insert or placebo comparator remaining the canaliculus longer than anticipated, performing more like an active comparator than a placebo.
We believe that the data from the small trial may inform the selection of a more appropriate placebo comparator for both the OTX-DED and the OTX-CSI programs moving forward. We currently expect this trial to begin in the first half of 2023. Also, we continue with the formulation work to extend the durability of the OTX-CSI insert. Our goal is to select the most appropriate formulation for the OTX-CSI program going forward.
I would now like to turn the call back over to Donald to review our second quarter financial results.
Donald Notman
Thanks, Rabia. Net revenue, which includes both gross product revenue net of discounts, rebates and returns, which the company refers to as total net product revenues and collaboration revenue was $12.3 million for the second quarter and represented an approximately 5% increase over the same period in 2021. Net product revenues of DEXTENZA in the second quarter of 2022 was $12.1 million versus $11.1 million in the comparable quarter of 2021, reflecting a 9% increase. Total net revenue for the second quarter of 2022 also included collaboration revenue of $0.1 million from our licensing agreement with Affimed.
Research and development expenses for the second quarter were $13.1 million versus $13.9 million for the comparable period in 2021, driven primarily by a reduction in clinical and preclinical spending, offset by an increase in unallocated personnel costs and other expenses. Selling and marketing expenses in the quarter were $10.1 million as compared to $8.4 million for the comparable quarter of 2021. Due primarily to an increase in professional fees related to trade shows, conferences and advertising.
General and administrative expenses were $7.8 million for the second quarter versus $8.6 million in the comparable quarter of 2021, primarily reflecting a decrease in professional fees. The company reported a net loss of $18.8 million or a loss of $0.24 per share on a basic basis and a loss of $0.25 per share on a diluted basis for the second quarter ended June 30, 2022.
This compares to a net loss of $8.5 million or a loss of $0.11 per share on a basic basis and a loss of $0.25 per share on a diluted basis for the same period in 2021. Net loss in the second quarter of 2022 was reduced by a $2.8 million noncash item attributable to a decrease in the fair value of the derivative liability associated with the company’s convertible notes as the price of its common stock declined during the quarter. Noncash charges for stock-based compensation and depreciation and amortization were $4.8 million in the second quarter versus $4.9 million for the same quarter in 2021.
As of August 5, 2022, the company had 77 million shares outstanding. As of June 30, 2022, the company had $134.5 million in cash and cash equivalents versus $145.4 million at March 31, 2022. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA and anticipated cash outflows from operating expenses, the company believes that its existing cash and cash equivalents are sufficient to enable the company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023.
This guidance is subject to a number of assumptions, including the impacts from the ongoing COVID-19 pandemic. The revenues, expenses and reimbursement associated with DEXTENZA and the pace of research and clinical development programs, among other aspects of the business.
I would now like to turn the call back over to Antony for some final thoughts.
Antony Mattessich
Thanks, Donald. So before opening the call up for questions, let me do a quick summary. All patients in the U.S.-based Phase I trial evaluated OTX-TKI in patients versus Eylea in wet AMD have now been on the study for at least 24 weeks, we’ve been run a late-breaker slot at the AAO, where we plan to present 28-week data. OTX-TIC continues to enroll patients in its Phase II trial for the treatment of open-angle glaucoma or ocular hypertension.
On our commercial business, DEXTENZA remains a source of tremendous opportunity. The proposed OPPS rule providing for separate reimbursement in the ASC through at least 2023. Despite the market still being hampered by staffing issues, we have great confidence in our ability to grow our surgical business and expand the extensive franchise even further as we add on the future potential of the office environment. We are reiterating our net product revenue guidance for 2022 of between $55 million to $60 million, representing approximately 26% to 38% year-over-year growth, driven predominantly by sales of DEXTENZA and surgical SAG.
Finally, the company ended the quarter with a strong balance sheet and $134.5 million in cash as of June 30, which we believe is sufficient to fund multiple development milestones and provide cash runway through 2023. We look forward to a strong remaining 2022. And with that, I will turn the call over to questions.
Question-and-Answer Session
Operator
[Operator Instructions]. Your first question comes from the line of Jon Wolleben from JMP Securities.
Jonathan Wolleben
Maybe starting with DEXTENZA Xtend and then I got a follow-up on TKI. Getting what gives you confidence that you’ll see the staffing issues that ASC bounce back in the second half of the year to reiterate your guidance? And then you mentioned you’re a little understaffed, wondering if you could provide a little more color on what’s going on with your reps as well?
Antony Mattessich
Yes, the confidence is just essentially the confidence that you have in the overall economy that things are going to normalize. And we do think there will be a number of factors that will improve as the year goes on. I think it’s really important the OPPS ruling that gives us continued visibility in 2023. I think that will give people comfort to be able to continue to stock up in the final quarter and maybe to move some volume over to DEXTENZA as well. But yes, it would look like $55 million to $60 million was something we were highly, highly confident of at one point, it’s going to be a little bit of a stretch. We still think we can get there. We think that the market is going to break in positive ways for us moving forward.
Jonathan Wolleben
And to TKI, just thinking about the translatability of the 3B cohort in Australia, Wondering if you could discuss the sequence of the anti-VEGF administration and TKI from that study and what you’re doing in the U.S. study. And then any differences in the logistics of the insert between the 600 micrograms and the 200-microgram inserts as far as besides just a dose of the drug, but any differences in the hydrogel there either we should think about?
Antony Mattessich
Rabia, you want to go ahead and answer that?
Rabia Ozden
Sure. And thank you for the question, Jon. Maybe I’ll just give a background about the Australia trial first, that Australia trial is designed to provide the safety and tolerability of OTX-TKI and they show preliminary biological activity in patients with the active subretinal and/or intraretinal fluid.
And the — that was that is a dose escalation trial and we started with a single implant of 200 micrograms then the 2 implants and then 3 implants, we reached to 600-microgram loading dose for those 3 implants.
3b cohorts in that trial is 2 implants, 200-microgram implants with an anti-VEGF injection. But again, we should remember that study was done in patients with active retinal fluid. What we have seen was that the some subjects, we have seen the fluid were decreased and kept that way for a duration of time, at least 6 months and some pipe subjects, the fluid was completely eliminated. And we have seen durability of that keeping the dry — keeping the retina dry for, again, at least 6 months. The most of the subjects, I should say, all subjects at least 50% and the group 3 it was cohort 3 was about 82% of the subjects were kept dry. The — at least 6 months.
That being said, coming to the Phase 1 in U.S., we have a singular implant, which is 600-microgram loading dose. But that study is being done in subjects with already dry retina. The subjects were enrolled in the trial with dry retinas and we are actually trying to answer the question, a single implant would keep the retina dry, how long it would keep the retina dry, and that’s what we are looking. To your question, is — and the data we’re going to present at AAO is going to be the 28-week follow-up data of the U.S. Phase I trial.
The question you’re asking is that the implant, it’s the dose, of course, is different and also 200 versus 600 in a single implant. And actually, we had a single implant in the eye. What we have observed in some patients, the patients — if we increase the number of the implants, patients were actually distort visually, they were seeing the implant sometimes from time to time in their visual access. That’s the other difference compared to Australia trial.
Operator
Your next question comes from the line of Dane Leone from Raymond James.
Unidentified Analyst
This is Sean on for Dane. Can I just a question on OTX-DED for us. For the new trial, can you kind of put some bounds around what you mean by short-lived comparator for the collagen implants and kind of what you’re expecting for the amount of time until degradation? And then maybe give us a little bit of characterization of what you’re thinking for in terms of material whether or not that would be sufficiently similar to what you’re looking at for the hydrogel or if you wanted to be markedly different in how you’re thinking about designing that trial?
Antony Mattessich
Rabia, you want to go ahead and answer that?
Rabia Ozden
Sure. Maybe again, like quick information on our Phase II trial with DED. That trial was a doublet trial of 0.2 and 0.3 dexamethasone compared to our hydrogel vehicle. We were able to hit the primary endpoint in that trial, primary endpoint of novel contractible redness we were able to just show a differentiation compared to hydrogel vehicle. What we have seen, though, the effect of the placebo comparator values, which is hydrogel vehicle actually behaves like an active comparator, the placebo effect, the magnitude that the effect was larger than you would expect it from a real true placebo. That was — that exact same thing we have seen also in our CSI Phase II trial.
What we are now trying to derisk our upcoming development program is actually trying to find a more appropriate placebo, a real placebo cooperator. What we are going to — what we are planning to study is this the commercially available soft collagen plug, which is like 2 to 5 days, staying in the canaliculus and then it would just disappear. That like that would actually provide a true placebo in a way that the patients would rate inserted during the trial, the are active versus this placebo patient wouldn’t feel the difference.
And then ultimately, is this collagen plug is quickly dissolved, but quickly dissolve would actually provide that true placebo comparator in our trial. That’s what we would like to study and see of the commercially available collagen plug is going to provide that through placebo for our trial. — so that we can derisk our upcoming Phase II/III drives.
Operator
Your next question comes from the line of Stacy Ku from Cowen.
Stacy Ku
Congratulations on the quarter. We have a few questions all on OTX-TKI. So as we await the Phase I results, just first, can you remind us the rescue criteria? And maybe you’ve kind of set the expectations in the past, but can we discuss the safety considerations, what profile looking for? That’s the first question.
And then the second question, just also discuss your early thoughts on the potential retreatment trial design or at the very least, could you discuss what a potential Phase 2 or 3 might look like in more details what steps are you taking considering for the next study? And then our last question is, what are the other potential retinal indications where you think OTX-TKI could be competitive? Maybe just discuss some potential opportunities you thought about where there might be additional unmet need.
Antony Mattessich
That’s a few questions, Rabia you want a stab at trying to answer that?
Rabia Ozden
Sure. Thank you so much, Stacy. Those are really great questions. Maybe I’m going to start with the rescue criteria. In both our Australia trial and the Australia trial, again, the patient population if what we call more difficult because those patients came into trial with active retinal fluids and the — and it was our first in-human study, and we have a rescue criteria. It’s as we — we share the dose criteria.
And I can just comment that dose criteria not only like safety of the patient was really too for those criteria. And what we try to do — just make sure that the disease state is answered when the investigators, the doctors are treating are study patients. The disease state is also considered during the trial. And the rescue criteria is designed that way.
And I can say they are the treatment retreatment criteria has somewhat lower bar compared to the other trials, the TKI trial. When we move into U.S. Phase I trial, the patients coming in, they had like more controlled patients because they came into trial with dry retina. And the — we again kept our criteria strict. Again, we have a very similar criteria to Australia trial. And we just wanted to make sure the investigators, there’s always another criteria, which is investigator discretion, that was also considered when the rescue treatment is done.
That’s why like in summary, I can say our criteria at their shares by everyone is more strict and the like at least the — and also including the disease take consideration by the investigators. We are looking at not only in our Australia trial, ultimately, that’s exactly what we plan to do in our Phase I trial just understanding how the rescue is done to inform our further study. That’s for the first question.
And I think that also answers the retreatment question for the Phase II, III, the retreatment criteria, rescue criteria that you would see in the plant trials is very similar to what we currently use in our Phase I trials. That’s how I can say. And we would just further discuss. But I think we would just in our upcoming studies include the disease state considerations more in the design or better retreatment criteria.
And your third question was other retinal indications. There are like the other retinal indications out there that tried by everyone for other drugs that you would use in the treatment of patients. Of course, diabetic retinopathy, DME, all of those are open up in front of us. What we think is that our studies but so far in TKI, not just 1 but 2 Phase I trials. We believe that we are in a great position having the data in different populations in the AMD, having opportunities seeing like studying different number of the implants with various doses.
We do think that — and also Dr. Peter Kaiser, Peter, working more closely with us. We’re going to just do our strategy in other retinal diseases in a more informed fashion going forward.
Operator
[Operator Instructions]. Your next question comes from Yi Chen from H.C. Wainwright.
Yi Chen
This is Yi. First question is, within your net product revenue guidance of $55 million to $60 million, how much of those would come from DEXTENZA for allergic conductivities this year?
Antony Mattessich
We’ve guided that it’s predominantly — or it’s reliably from the surgical setting. We have not guiding for a large number in the other conjunctivitis because we are doing a beta test at the moment.
Yi Chen
Okay. Can you comment on the potential sales in AC for 2023 at this point?
Antony Mattessich
No, we haven’t guided to what those sales will be in 2023 at this point.
Yi Chen
How many people are currently in the chain dedicated to AC?
Antony Mattessich
We have a team of 4 key account managers. We’ve staffed up now for about a little over a month. We have a field reimbursement specialist and manager for the team.
Yi Chen
Okay. And how large is the entire sales team right now?
Antony Mattessich
40 key account managers, and we have about 7 or 8 field reimbursement specialists and then 3 regional people.
Yi Chen
Got it. And so in the current U.S. TKI trial, what is the average anti-VEGF injections do these patients had before enrollment into the trial?
Antony Mattessich
Rabia, you want to have that?
Rabia Ozden
Sure. We are collecting that data and that data is going to be shared with everyone in the upcoming AAO med.
Yi Chen
Okay. All right. For the TIC Phase II trial, when do you expect to complete enrollment?
Rabia Ozden
We have not guided the completion date for TIC Phase II trials. Again, just to maybe give quick background, that’s a Phase II double mat randomized trial with 2 formulations of OTX-TIC compared to Vista in patients with open-angle glaucoma and ocular hypertension.
We’re going to enroll 105 subjects in these 3 arms. And the enrollment is currently going well. And the — again, we just would like to just continue moving and then just some time later, guide when we expect the enrollment would be finished.
Operator
Your next question comes from the line of Joe Catanzaro from Piper Sandler.
Joseph Catanzaro
This is Albert on for Joe. Just a quick one for me. I was wondering if we can still expect to see an update from the Australia trial later this year?
Rabia Ozden
Joe, yes, we would like to do an update on Australia trial in the upcoming AAO meeting as well.
Operator
There are no further questions at this time. This concludes today’s conference call. You may now disconnect.
Be the first to comment